Influence of flare design on symptomatic efficacy of non-steroidal anti-inflammatory drugs in osteoarthritis: A meta-analysis of randomized placebo-controlled trials

Osteoarthritis and Cartilage

Volumn 18, Issue 8, 2010, Pages 1012-1018

  Trijau, S ^a,b   Avouac, J ^a,b   Escalas, C ^a,b   Gossec, L ^a,b   Dougados, M ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b Rheumatology B Department ^*  (France)

Author keywords

Flare; NSAIDs; Osteoarthritis; Study design

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE EXACERBATION; DRUG EFFICACY; HAND DISEASE; HAND OSTEOARTHRITIS; HIP OSTEOARTHRITIS; HUMAN; KNEE OSTEOARTHRITIS; LEQUESNE INDEX; META ANALYSIS; OSTEOARTHRITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCORING SYSTEM; SYSTEMATIC REVIEW; VISUAL ANALOG SCALE; WESTERN ONTARIO OSTEOARTHRITIS AND MCMASTER UNIVERSITIES INDEX;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; OSTEOARTHRITIS; PAIN; PAIN MEASUREMENT; PLACEBOS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SEVERITY OF ILLNESS INDEX; STATISTICS AS TOPIC; TREATMENT OUTCOME;

EID: 77954658531     PISSN: 10634584     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joca.2010.04.005     Document Type: Review

References (51)

1. Wright V. Osteoarthritis. Br Med J 1989, 299:1476-1477.
2. Felson D.T. Epidemiology of hip and knee osteoarthritis. Epidemiol Rev 1988, 10:1-28.
3. Jordan K.M., Arden N.K., Doherty M., Bannwarth B., Bijlsma J.W., Dieppe P., Standing Committee for International Clinical Studies Including Therapeutic Trials ESCISIT, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003, 62:1145-1155.
4. Zhang W., Doherty M., Arden N., Bannwarth B., Bijlsma J., Gunther K.P., EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT), et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2005, 64:669-681.
5. Altman R., Alarcón G., Appelrouth D., Bloch D., Borenstein D., Brandt K., et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum 1991, 34:505-514.
6. Altman R., Alarcón G., Appelrouth D., Bloch D., Borenstein D., Brandt K., et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand. Arthritis Rheum 1990, 33:1601-1610.
7. Altman R., Asch E., Bloch D., Bole G., Borenstein D., Brandt K., et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Arthritis Rheum 1986, 29:1039-1049. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association.
8. Bellamy N., Buchanan W.W., Goldsmith C.H., Campbell J., Stitt L.W. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988, 15:1833-1840.
9. Lequesne M. Indices of severity and disease activity for osteoarthritis. Semin Arthritis Rheum 1991, 20(Suppl 2):48-54.
10. Jadad A.R., Moore R.A., Carroll D., Jenkinson C., Reynolds D.J., Gavaghan D.J., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996, 17:1-12.
11. Practical meta-analysis. Lipsey MW. 2001;49:13.
12. Cohen J. A power primer. Psychol Bull 1992, 112(1):155-159.
13. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21:1539-1558.
14. Bingham C.O., Sebba A.I., Rubin B.R., Ruoff G.E., Kremer J., Bird S., et al. Efficacy and safety of etoricoxib 30mg and celecoxib 200mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies. Rheumatology (Oxford) 2007, 46:496-507.
15. Wittenberg R.H., Schell E., Krehan G., Maeumbaed R., Runge H., Schlüter P., et al. First-dose analgesic effect of the cyclo-oxygenase-2 selective inhibitor lumiracoxib in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled comparison with celecoxib [NCT00267215]. Arthritis Res Ther 2006, 8:R35.
16. Birbara C., Ruoff G., Sheldon E., Valenzuela C., Rodgers A., Petruschke R.A., et al. Efficacy and safety of rofecoxib 12.5mg and celecoxib 200mg in two similarly designed osteoarthritis studies. Curr Med Res Opin 2006, 22:199-210.
17. Schnitzer T.J., Kivitz A.J., Lipetz R.S., Sanders N., Hee A. Comparison of the COX-inhibiting nitric oxide donator AZD3582 and rofecoxib in treating the signs and symptoms of osteoarthritis of the knee. Arthritis Rheum 2005 Dec 15, 53(6):827-837.
18. Svensson O., Malmenäs M., Fajutrao L., Roos E.M., Lohmander L.S. Greater reduction of knee than hip pain in osteoarthritis treated with naproxen, as evaluated by WOMAC and SF-36. Ann Rheum Dis 2006, 65(6):781-784.
19. Fleischmann R., Sheldon E., Maldonado-Cocco J., Dutta D., Yu S., Sloan V.S. Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a prospective randomized 13-week study versus placebo and celecoxib. Clin Rheumatol 2006, 25(1):42-53.
20. Lehmann R., Brzosko M., Kopsa P., Nischik R., Kreisse A., Thurston H., et al. Efficacy and tolerability of lumiracoxib 100mg once daily in knee osteoarthritis: a 13-week, randomized, double-blind study vs. placebo and celecoxib. Curr Med Res Opin 2005, 21(4):517-526.
21. Wiesenhutter C.W., Boice J.A., Ko A., Sheldon E.A., Murphy F.T., Wittmer B.A., Protocol 071 Study Group, et al. Evaluation of the comparative efficacy of etoricoxib and ibuprofen for treatment of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2005, 80(4):470-479.
22. Sheldon E., Beaulieu A., Paster Z., Dutta D., Yu S., Sloan V.S. Efficacy and tolerability of lumiracoxib in the treatment of osteoarthritis of the knee: a 13-week, randomized, double-blind comparison with celecoxib and placebo. Clin Ther 2005, 27:64-77.
23. Grifka J.K., Zacher J., Brown J.P., Seriolo B., Lee A., Moore A., et al. Efficacy and tolerability of lumiracoxib versus placebo in patients with osteoarthritis of the hand. Clin Exp Rheumatol 2004, 22(5):589-596.
24. Lohmander L.S., McKeith D., Svensson O., Malmenäs M., Bolin L., Kalla A., STAR Multinational Study Group, et al. A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis. Ann Rheum Dis 2005, 64(3):449-456.
25. Schnitzer T.J., Beier J., Geusens P., Hasler P., Patel S.K., Senftleber I., et al. Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: a phase II, four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2004, 51:549-557.
26. Kivitz A.J., Greenwald M.W., Cohen S.B., Polis A.B., Najarian D.K., Dixon M.E., Protocol 085 Study Investigators, et al. Efficacy and safety of rofecoxib 12.5mg versus nabumetone 1000mg in patients with osteoarthritis of the knee: a randomized controlled trial. J Am Geriatr Soc 2004, 52:666-674.
27. Tannenbaum H., Berenbaum F., Reginster J.Y., Zacher J., Robinson J., Poor G., et al. Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib. Ann Rheum Dis 2004, 63:1419-1426.
28. Case J.P., Baliunas A.J., Block J.A. Lack of efficacy of acetaminophen in treating symptomatic knee osteoarthritis: a randomized, double-blind, placebo-controlled comparison trial with diclofenac sodium. Arch Intern Med 2003, 163:169-178.
29. Gottesdiener K., Schnitzer T., Fisher C., Bockow B., Markenson J., Ko A., Protocol 007 Study Group, et al. Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis. Rheumatology (Oxford) 2002, 41:1052-1061.
30. Leung A.T., Malmstrom K., Gallacher A.E., Sarembock B., Poor G., Beaulieu A., et al. Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: a randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial. Curr Med Res Opin 2002, 18(2):49-58.
31. Makarowski W., Zhao W.W., Bevirt T., Recker D.P. Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: a randomized, double-blind, placebo-controlled comparison with naproxen. Osteoarthritis Cartilage 2002, 10:290-296.
32. Kivitz A.J., Moskowitz R.W., Woods E., Hubbard R.C., Verburg K.M., Lefkowith J.B., et al. Comparative efficacy and safety of celecoxib and naproxen in the treatment of osteoarthritis of the hip. J Int Med Res. 2001, 29(6):467-479.
33. Uzun H., Tuzun S., Ozaras N., Aydin S., Ozaras R., Dondurmaci S., et al. The effect of flurbiprofen and tiaprofenic acid on serum cytokine levels of patients with osteoarthrosis. Acta Orthop Scand 2001, 72(5):499-502.
34. Williams G.W., Hubbard R.C., Yu S.S., Zhao W., Geis G.S. Comparison of once-daily and twice-daily administration of celecoxib for the treatment of osteoarthritis of the knee. Clin Ther 2001, 23(2):213-227.
35. Lisse J., Espinoza L., Zhao S.Z., Dedhiya S.D., Osterhaus J.T. Functional status and health-related quality of life of elderly osteoarthritic patients treated with celecoxib. J Gerontol A Biol Sci Med Sci 2001, 56(3):M167-M175.
36. McKenna F., Borenstein D., Wendt H., Wallemark C., Lefkowith J.B., Geis G.S. Celecoxib versus diclofenac in the management of osteoarthritis of the knee. Scand J Rheumatol 2001, 30(1):11-18.
37. Day R., Morrison B., Luza A., Castaneda O., Strusberg A., Nahir M., et al. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Arch Intern Med 2000 Jun 26, 160(12):1781-1787. Rofecoxib/Ibuprofen Comparator Study Group.
38. Zhao S.Z., McMillen J.I., Markenson J.A., Dedhiya S.D., Zhao W.W., Osterhaus J.T., et al. Evaluation of the functional status aspects of health-related quality of life of patients with osteoarthritis treated with celecoxib. Pharmacotherapy 1999, 19(11):1269-1278.
39. Ehrich E.W., Schnitzer T.J., McIlwain H., Levy R., Wolfe F., Weisman M., et al. Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. J Rheumatol 1999, 26(11):2438-2447. Rofecoxib Osteoarthritis Pilot Study Group.
40. Davies G.M., Watson D.J., Bellamy N. Comparison of the responsiveness and relative effect size of the Western Ontario and McMaster Universities Osteoarthritis Index and the short-form Medical Outcomes Study Survey in a randomized, clinical trial of osteoarthritis patients. Arthritis Care Res 1999, 12(3):172-179.
41. Bocanegra T.S., Weaver A.L., Tindall E.A., Sikes D.H., Ball J.A., Wallemark C.B., et al. Diclofenac/misoprostol compared with diclofenac in the treatment of osteoarthritis of the knee or hip: a randomized, placebo controlled trial. J Rheumatol 1998 Aug, 25(8):1602-1611. Arthrotec Osteoarthritis Study Group.
42. Lund B., Distel M., Bluhmki E. A double-blind, randomized, placebo-controlled study of efficacy and tolerance of meloxicam treatment in patients with osteoarthritis of the knee. Scand J Rheumatol 1998, 27(1):32-37.
43. Bourgeois P., Dreiser R.L., Lequesne M.G., Macciocchi A., Monti T. Multi-centre double-blind study to define the most favourable dose of nimesulide in terms of efficacy/safety ratio in the treatment of osteoarthritis. Eur J Rheumatol Inflamm 1994, 14(2):39-50.
44. Dreiser R.L., Gersberg M., Thomas F., Courcier S. Ibuprofen 800mg in the treatment of arthrosis of the fingers or rhizarthrosis. Rev Rhum Ed Fr 1993 Nov 30, 60(11):836-841. (In French).
45. Lee P., Davis P., Prat A. The efficacy of diflunisal in osteoarthritis of the knee. J Rheumatol 1985, 12(3):544-548. A Canadian Multicenter Study.
46. Nguyen M., Dougados M., Berdah L., Amor B. Diacerhein in the treatment of osteoarthritis of the hip. Arthritis Rheum 1994, 37(4):529-536.
47. Bjordal J.M., Klovning A., Ljunggren A.E., Slørdal L. Short-term efficacy of pharmacotherapeutic interventions in osteoarthritic knee pain: a meta-analysis of randomised placebo-controlled trials. Eur J Pain 2007 Feb, 11(2):125-138.
48. McQuay H.J., Derry S., Moore R.A., Poulain P., Legout V. Enriched enrolment with randomised withdrawal (EERW): time for a new look at clinical trial design in chronic pain. Pain 2008, 135:217-220.
49. Lemmens H.J., Wada D.R., Munera C., Eltahtawy A., Stanski D.R. Enriched analgesics efficacy studies: an assessment by clinical trial simulation. Contemp Clin Trials 2006 Apr, 27(2):165-173.
50. D'Agostino M.A., Conaghan P., Le Bars M., Baron G., Grassi W., Martin-Mola E., et al. EULAR report on the use of ultrasonography in painful knee osteoarthritis. Part 1: prevalence of inflammation in osteoarthritis. Ann Rheum Dis 2005, 64(12):1703-1709.
51. Mazières B., Garnero P., Guéguen A., Abbal M., Berdah L., Lequesne M., et al. Molecular markers of cartilage breakdown and synovitis at baseline as predictors of structural progression of hip osteoarthritis. Ann Rheum Dis 2006, 65(3):354-359. The ECHODIAH Cohort.